7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A critical appraisal of the SCALE Obesity and Prediabetes trial (liraglutide 3.0 mg), examining enrollment biases, generalizability gaps, statistical caveats, and post-publication commentary.
A deep dive into the SCALE Obesity trial's randomization, blinding, inclusion criteria, statistical framework, and comparator design for liraglutide 3.0 mg in chronic weight management.
Deep-dive into the SCALE Obesity trial's extension phase, weight regain after liraglutide discontinuation, durability of cardiometabolic benefits, and long-term safety signals from 3 years of follow-up data.
Complete breakdown of the SCALE Obesity and Prediabetes trial results for liraglutide 3.0 mg, including primary and secondary endpoints, confidence intervals, response distribution, and weight-loss time course over 56 weeks.
Deep-dive into SCALE Obesity pre-specified and post-hoc subgroup analyses for liraglutide 3.0 mg, examining differential responses by age, sex, BMI, baseline biomarkers, and race/ethnicity.
A deep-dive into the SCALE Obesity and Prediabetes RCT (2015), explaining how liraglutide 3.0 mg demonstrated meaningful weight loss versus placebo over 56 weeks and what it means for clinical practice.
A deep-dive into the SCALE Obesity trial of liraglutide 3.0 mg, examining how its results reshaped weight-management guidelines, prescribing patterns, and real-world patient selection.